Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …

Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …

This report presents the recommendations of the WHO Expert Committee responsible for
updating the WHO Model Lists of Essential Medicines.. The goal of the meeting was to …

Background Despite the revolutionary success of introducing tyrosine kinase inhibitors
(TKIs), such as imatinib mesylate (IM), for treating chronic myeloid leukemia (CML), a …

Molecular monitoring plays an essential role in the clinical management of chronic myeloid
leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse …

Inadequate diagnostics compromise cancer care across lower-and middle-income countries
(LMICs). We hypothesized that an inexpensive gene expression assay using paraffin …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative growth of human pluripotent
stem cells which is estimated to occur at a rate of 1/100000 populations every year …

The level of BCR-ABL1 reached after treatment with tyrosine kinase inhibitors is an effective
marker of the therapeutic response and a good survival predictor in chronic myeloid …

Currently, physicians treating chronic myeloid leukaemia (CML) patients can rely on a wide
spectrum of therapeutic options: the best use of such options is essential to achieve …

Breakpoint cluster region-Abelson (BCR-ABL1) translocation is the characteristic sign of
chronic myeloid leukemia (CML). The quantitation of BCR-ABL1 messenger RNA is …